关于《振德医疗用品股份有限公司股票交易异常波动 间询函》的回函 振德医疗用品股份有限公司: 本公司于 2026 年 2 月 10 日收到贵公司发来的《振德医疗用品股 份有限公司股票交易异常波动问询函》,经自查核实,回复如下: 本公司作为振德医疗用品股份有限公司控股股东,截止目前,不 存在影响贵公司股票交易异常波动的重大事项,不存在应披露而未披 露的重大信息，包括但不限于重大资产重组、发行股份、上市公司收 购、债务重组、业务重组、资产剥离、资产注入、股份回购、股权激 励、破产重整、重大业务合作、引进战略投资者等重大事项。 沈振芳 鲁建国 2026 年 2 月 10 日 关于《振德医疗用品股份有限公司股票交易异常波动 间询函》的回函 振德医疗用品股份有限公司: 本人于 2026 年 2 月 10 日收到贵公司发来的《振德医疗用品股份 有限公司股票交易异常波动问询函》,经自查核实,回复如下: 本人作为振德医疗用品股份有限公司实际控制人,截止目前,不 存在影响贵公司股票交易异常波动的重大事项,不存在应披露而未披 露的重大信息,包括但不限于重大资产重组、发行股份、上市公司收 购、债务重组、业务重组、资产剥离、资产注入、 ...

Core Viewpoint - Zhendemedical has experienced a consecutive two-day trading limit increase, indicating strong market interest and potential investor confidence [1] Group 1: Stock Performance - Zhendemedical's stock reached a trading limit at 9:58 AM with a transaction volume of 453 million yuan and a turnover rate of 1.96% [1] Group 2: Corporate Governance and Strategy - The company is optimizing its corporate governance structure by introducing a stock ownership plan for core employees and establishing a mechanism for repurchasing and canceling unblocked shares, which is expected to enhance team stability [1] - Zhendemedical is also engaging in hedging activities to mitigate risks associated with raw material price fluctuations, ensuring stable production costs [1] Group 3: Industry Context - Other companies within the pharmaceutical sector are showing positive performance due to improved governance and stable business operations, contributing to a sector-wide synergy effect [1]

Group 1 - On February 9, 2026, Zhendemedical (603301) closed at 80.69 yuan, up 10.01%, reaching the daily limit with a turnover rate of 1.76% and a trading volume of 46,800 lots, resulting in a transaction amount of 373 million yuan [1] - The net inflow of main funds on February 9 was 75.55 million yuan, accounting for 20.25% of the total transaction amount, while retail investors experienced a net outflow of 29.04 million yuan, representing 7.78% of the total transaction amount [1] - Over the past five days, the stock has shown a price increase of 10.01% on February 9, with a previous increase of 4.86% on February 6, and a decrease of 0.63% on February 5 [2] Group 2 - As of February 9, 2026, the financing balance for Zhendemedical was 1.372 billion yuan, with a net repayment of 104 million yuan on that day [3] - The stock's financing buy on February 9 was 39.69 million yuan, while the financing repayment was 143 million yuan [3] - The stock's short selling on February 9 involved 100 shares sold, with a remaining short selling balance of 1.55 million shares valued at 1.2507 million yuan [3] Group 3 - Zhendemedical's total market value is 21.45 billion yuan, with a net asset value of 5.985 billion yuan and a net profit of 203 million yuan [5] - The company's price-to-earnings ratio (P/E) is 79.18, while the industry average is 65.68, indicating a higher valuation compared to peers [5] - The gross profit margin for Zhendemedical is 33.93%, significantly lower than the industry average of 50.61%, and the net profit margin is 6.61%, compared to the industry average of 9.71% [5] Group 4 - In the third quarter of 2025, Zhendemedical reported a main revenue of 3.184 billion yuan, a year-on-year increase of 1.88%, while the net profit decreased by 33.91% to 203 million yuan [5] - The company's debt ratio stands at 28.78%, with investment income of 8.4885 million yuan and financial expenses of 26.0941 million yuan [5] - The company specializes in the production and sale of basic care, surgical infection control, pressure treatment and fixation, stoma and modern wound care, and infection control protection products [5]

Core Viewpoint - The company, ZhenDe Medical, has decided to cancel repurchased shares and reduce its registered capital, impacting its total share capital and registered capital amounts. Group 1: Share Repurchase and Capital Reduction - The company will cancel a total of 1,959,310 shares, which includes 129,442 shares already repurchased and 1,829,868 shares from the second phase of the employee stock ownership plan that have not been unlocked. This change will alter the total share capital from 265,835,535 shares to 263,876,225 shares and reduce the registered capital from 265,835,535 yuan to 263,876,225 yuan [1][2]. Group 2: Notification to Creditors - Creditors are notified that they have 30 days from receiving the notice, or 45 days from the announcement date if no notice is received, to claim their debts or request guarantees. Failure to act within this timeframe will not affect the validity of their claims, and the company will continue to fulfill its obligations as per the original debt agreements [2]. Group 3: Debt Claim Submission Requirements - Creditors must provide original and copies of documents proving the existence of the debt relationship when submitting claims. Legal entities must also present their business license and identification of their legal representative, while individuals must provide valid identification [3]. Group 4: Debt Claim Submission Methods - Claims can be submitted in person, by mail, or via email. The submission period starts from February 10, 2026, and lasts for 45 days. Contact details for submissions include a physical address, phone number, and email [4][5].

Group 1 - The core point of the article is that Zhendemedical (603301) experienced a significant increase in stock price, closing at 80.69 yuan with a 10.01% rise, reaching the daily limit [1] - On February 9, the stock hit the daily limit at 9:48 AM and did not open again, with a closing order amount of 1.95 billion yuan, accounting for 0.91% of its circulating market value [2] - The trading volume was 46,800 hands, with a total transaction amount of 373 million yuan [1] Group 2 - The net inflow of main funds was 75.5463 million yuan, representing 20.25% of the total transaction amount, indicating a clear accumulation trend [2] - Retail investors showed a net outflow of 29.0449 million yuan, which accounted for 7.78% of the total transaction amount [1] - The outflow of speculative funds was 46.5014 million yuan, making up 12.46% of the total transaction amount [1]

公司本次注销回购股份将导致公司注册资本减少，根据《中华人 民共和国公司法》(以下简称"《公司法》")等相关法律法规的规定， 公司特此通知债权人，债权人自接到公司通知起 30 日内、未接到通 知者自本公告之日起 45 日内，均有权凭有效债权文件及相关凭证要 求公司清偿债务或者提供相应担保。债权人未在规定期限内行使上述 权利的，不会影响其债权的有效性，相关债务将由公司根据原债权文 件的约定继续履行，本次注销回购股份将按法定程序继续实施。 公司债权人如要求公司清偿债务或提供相应担保的，应根据《公 司法》等法律法规的有关规定向公司提出书面要求，并随附有关证明 文件。 （一）债权申报所需材料 证券代码：603301 证券简称：振德医疗 公告编号：2026-012 振德医疗用品股份有限公司 关于注销回购股份减少注册资本 暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 振德医疗用品股份有限公司（以下简称"公司"）分别于 2026 年 1 月 23 日、2 月 9 日召开第四届董事会第六次会议及 20 ...

北京国枫（杭州）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2026 年第二次临时股东会（以下简称"本次会议"）。 杭州市上城区新业路 8 号华联时代大厦 B 幢 22 层 电话：0571-88362156 传真：0571-88362156 邮编：310016 北京国枫（杭州）律师事务所 关于振德医疗用品股份有限公司 2026 年第二次临时股东会的 法律意见书 国枫律股字[2026] G0002 号 致：振德医疗用品股份有限公司（贵公司） 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律 业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《振德医疗用品股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法 ...

证券代码：603301 证券简称：振德医疗 公告编号：2026-011 振德医疗用品股份有限公司 2026年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 86 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 146,155,294 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 54.9795 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，以现场投票和网络投票相结合的方式召开，由 董事长鲁建国先生主持会议。本次会议的召集、召开及表决方式符合《公司法》 及《公司章程》的规定。 审议结果：通过 (一) 股东会召开的时间：2026 年 2 月 9 日 (二) 股东会召开的地点：浙江 ...

Core Viewpoint - Zhendemedical (603301) has seen a price increase of 6.66% this week, closing at 73.35 yuan as of February 6, 2026, with a total market capitalization of 19.499 billion yuan [1] Company Announcements - Zhendemedical announced a change in the project quality reviewer, with Wang Wen taking over from Zheng Chuanxian due to work adjustments [1] - Wang Wen has been a certified public accountant since 2011 and has been providing audit services to the company since 2025, ensuring independence and no penalties for professional conduct [1] - The change in the quality reviewer will not affect the normal conduct of the company's 2025 financial statement and internal control audit [1]

Group 1 - On February 6, 2026, Zhendemedical (603301) closed at 73.35 yuan, an increase of 4.86%, with a turnover rate of 1.49% and a trading volume of 39,700 hands, resulting in a transaction amount of 286 million yuan [1] - The net inflow of main funds on February 6 was 12.68 million yuan, accounting for 4.43% of the total transaction amount, while retail investors had a net outflow of 15.85 million yuan, accounting for 5.54% of the total transaction amount [1] - The financing data on February 6 showed a financing buy-in of 110 million yuan and a net financing buy-in of 55.78 million yuan, with a financing balance of 1.475 billion yuan [2][3] Group 2 - Zhendemedical's total market value is 19.499 billion yuan, with a net asset of 5.985 billion yuan and a net profit of 203 million yuan, ranking 15th, 21st, and 29th respectively in the medical device industry [5] - The company's gross profit margin is 33.93%, which is lower than the industry average of 50.55%, and its net profit margin is 6.61%, compared to the industry average of 9.59% [5] - In the first three quarters of 2025, Zhendemedical's main revenue was 3.184 billion yuan, a year-on-year increase of 1.88%, while the net profit decreased by 33.91% to 203 million yuan [5]